Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

PURPOSE: Several adjuvant phase III trials are evaluating cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET) in hormonal receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) early-stage breast cancer (eBC). This study examines pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Beusterien, Kathleen, Maculaitis, Martine C, Hallissey, Bernadette, Gaschler, Michael M, Smith, Mary Lou, Law, Ernest H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987325/
https://www.ncbi.nlm.nih.gov/pubmed/33776424
http://dx.doi.org/10.2147/PPA.S298670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987325/
https://www.ncbi.nlm.nih.gov/pubmed/33776424
http://dx.doi.org/10.2147/PPA.S298670

Ejemplares similares